Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cue Biopharma stock

Own Cue Biopharma stock in just a few minutes.

Cue Biopharma, Inc is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Cue Biopharma employs 50 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cue Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CUE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cue Biopharma share price

Use our graph to track the performance of CUE stocks over time.

Cue Biopharma shares at a glance

Information last updated 2021-04-29.
52-week range$10.75 - $31.69
50-day moving average $12.87
200-day moving average $13.23
Wall St. target price$30.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.20

Buy Cue Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cue Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cue Biopharma financials

Revenue TTM $3.2 million
Gross profit TTM $-30,391,380
Return on assets TTM -32.9%
Return on equity TTM -67.1%
Profit margin 0%
Book value $2.60
Market capitalisation $364.3 million

TTM: trailing 12 months

Shorting Cue Biopharma shares

There are currently 2.9 million Cue Biopharma shares held short by investors – that's known as Cue Biopharma's "short interest". This figure is 7.9% down from 3.1 million last month.

There are a few different ways that this level of interest in shorting Cue Biopharma shares can be evaluated.

Cue Biopharma's "short interest ratio" (SIR)

Cue Biopharma's "short interest ratio" (SIR) is the quantity of Cue Biopharma shares currently shorted divided by the average quantity of Cue Biopharma shares traded daily (recently around 293035.19269777). Cue Biopharma's SIR currently stands at 9.86. In other words for every 100,000 Cue Biopharma shares traded daily on the market, roughly 9860 shares are currently held short.

However Cue Biopharma's short interest can also be evaluated against the total number of Cue Biopharma shares, or, against the total number of tradable Cue Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cue Biopharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cue Biopharma shares in existence, roughly 90 shares are currently held short) or 0.0979% of the tradable shares (for every 100,000 tradable Cue Biopharma shares, roughly 98 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cue Biopharma.

Find out more about how you can short Cue Biopharma stock.

Cue Biopharma share dividends

We're not expecting Cue Biopharma to pay a dividend over the next 12 months.

Cue Biopharma share price volatility

Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $10.75 up to $31.69. A popular way to gauge a stock's volatility is its "beta".

CUE.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.8523. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cue Biopharma overview

Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site